Back
Compare AU
Compare IAF vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Core Composite Bond ETF (IAF) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IAF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 516 | 72 |
Median incremental investment | $1,071.39 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,139.99 | $1,980.16 |
Average age group | > 35 | > 35 |
Key Summary
IAF | DRUG | |
|---|---|---|
Strategy | IAF.AX was created on 2012-03-12 by iShares. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 3247.06m in AUM and 594 holdings. The fund aims to provide investors with the performance of the Bloomberg AusBond Composite 0+ Yr IndexSM, before fees and expenses. The index is designed to measure the performance of the Australian bond market and includes investment grade fixed income securities issued by the Australian Treasury. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | AUSTRALIA (COMMONWEALTH OF) RegS (2.49 %) AUSTRALIA (COMMONWEALTH OF) RegS (2.44 %) AUSTRALIA (COMMONWEALTH OF) RegS (2.40 %) | AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) BRL - BRAZILIAN REAL (0 %) |
Top 3 industries | Other (99.31 %) Financials (0.25 %) Communication Services (0.19 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) | |
Management fee | 0.15 % | 0.57 % |
Key Summary
IAF | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | Bloomberg AusBond Composite 0+ Yr Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.15 % | 0.57 % |
Price | $101.17 | $8.84 |
Size | $3.743 billion | $174.658 million |
10Y return | -7.39 % | 78.23 % |
Annual distribution yield (5Y) | 2.22 % | 1.82 % |
Market | ASX | ASX |
First listed date | 14/03/2012 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IAF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 516 | 72 |
Median incremental investment | $1,071.39 | $740.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,139.99 | $1,980.16 |
Average age group | > 35 | > 35 |
Pros and Cons
IAF | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IAF | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |